Clonazepam

Overview

Clonazepam (Klonopin®) is a benzodiazepine anticonvulsant used in veterinary medicine primarily for seizure control and management of anxiety-related disorders in dogs and cats. It is most commonly used as adjunctive therapy for epilepsy, particularly in cats for long-term management and in dogs for short-term seizure control.

In addition to its anticonvulsant effects, clonazepam may be used as an anxiolytic and muscle relaxant in small animals. The drug has a relatively long duration of action compared with some other benzodiazepines and may be selected when longer-lasting sedation or anxiety control is desired. However, tolerance to its anticonvulsant effects may develop in dogs after several weeks of therapy.

Mechanism of Action (MOA): Clonazepam acts on the central nervous system by enhancing the effects of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Benzodiazepines depress subcortical brain regions including the limbic system, thalamus, and hypothalamus, resulting in anticonvulsant, anxiolytic, sedative, and skeletal muscle-relaxant effects.

Indications

Clonazepam is used in dogs and cats primarily for neurologic and behavioral conditions where anticonvulsant, anxiolytic, or muscle-relaxant effects are desired. In veterinary practice it is most often used as an adjunctive medication rather than a primary therapy.

• Adjunctive therapy for epilepsy: Used to help control seizures when additional anticonvulsant support is needed. It is more commonly used for long-term adjunctive seizure management in cats and short-term adjunctive therapy in dogs.
• Anxiety and behavioral disorders: May be used as an anxiolytic in dogs and cats, particularly when a longer-acting benzodiazepine is preferred for behavior modification programs.
• Muscle hypertonicity: Used in dogs for management of episodic falling syndrome associated with muscular hypertonicity, particularly in Cavalier King Charles Spaniels.
• Feline hyperesthesia syndrome: May be used in cats to help reduce neurologic or behavioral signs associated with hyperesthesia.

Dosage (Reference)

Dog

In dogs, clonazepam is most commonly used as adjunctive therapy for seizure control or for anxiety-related conditions. The dose may vary widely depending on the clinical indication and individual patient response.

Cat

In cats, clonazepam may be used as adjunctive therapy for seizure control or for behavioral conditions such as anxiety or hyperesthesia. Dosing is typically expressed as a fixed dose per cat rather than by body weight.

Warnings & Precautions

Clonazepam should be used cautiously in dogs and cats because of its effects on the central nervous system and its hepatic metabolism. Careful patient selection and monitoring are recommended, particularly during long-term therapy or in animals with underlying medical conditions.

• Hypersensitivity: Clonazepam is contraindicated in animals with known hypersensitivity to benzodiazepines.
• Severe liver disease: Use is contraindicated in patients with significant hepatic dysfunction because the drug is metabolized in the liver.
• Narrow-angle glaucoma: Benzodiazepines should not be used in animals with acute narrow-angle glaucoma.
• Myasthenia gravis: Benzodiazepines may worsen muscle weakness and should be avoided or used cautiously in patients with myasthenia gravis.
• Renal or hepatic impairment: Use cautiously in animals with kidney or liver dysfunction and monitor clinical response carefully.
• Aggressive animals: Clonazepam may alter behavior and should be used cautiously in aggressive patients.
• Tolerance development: Dogs may develop tolerance to the anticonvulsant effects after several weeks of therapy, which may reduce clinical effectiveness.
• Withdrawal precautions: In animals receiving long-term therapy, clonazepam should not be discontinued abruptly. Gradual tapering is recommended to avoid withdrawal signs or seizure recurrence.
• Xylitol-containing formulations: Orally disintegrating tablets that contain xylitol should be used cautiously in dogs.
• Handling precautions: Clonazepam is classified as a hazardous drug by NIOSH; appropriate precautions should be taken when handling the medication.

Drug Interactions

Clonazepam may interact with several medications that affect the central nervous system, hepatic metabolism, or cardiovascular function. Most interactions involve additive sedation, altered drug metabolism, or increased risk of adverse neurologic or cardiovascular effects.

• Anesthetic agents (e.g., alfaxalone, dexmedetomidine, isoflurane, propofol): Concurrent use may increase sedation and respiratory depression.
• Opioids (e.g., buprenorphine, fentanyl, methadone, morphine, tramadol): May cause profound sedation and respiratory depression when used together.
• Phenothiazines (e.g., acepromazine): Additive central nervous system depression may occur.
• Anticholinergic agents (e.g., atropine, glycopyrrolate): Anticholinergic effects may be enhanced when used concurrently.
• Azole antifungals (e.g., itraconazole, ketoconazole): May increase clonazepam concentrations by reducing hepatic metabolism.
• Cimetidine: May inhibit metabolism of benzodiazepines and increase clonazepam levels.
• Rifampin: May induce hepatic enzymes and reduce the pharmacologic effects of clonazepam.
• Phenobarbital or phenytoin: May decrease clonazepam concentrations and reduce clinical effectiveness.
• Digoxin: Concurrent use may increase digoxin concentrations and risk of toxicity; monitoring is recommended.
• Antihypertensive drugs (e.g., amlodipine, benazepril, telmisartan): Increased risk of hypotension may occur when used together.
• Cannabinoids (e.g., cannabidiol): Additive CNS depression may occur.
• Yohimbine: May reduce the therapeutic anxiolytic effects of clonazepam.

Side Effects & Overdose

Side Effects

Reported adverse effects of clonazepam in dogs and cats are mainly related to central nervous system depression. Available veterinary data are limited, but effects are generally consistent with those seen with other benzodiazepines.

• Sedation: Drowsiness or decreased activity is the most commonly observed effect.
• Ataxia: Uncoordinated gait or weakness may occur, especially when therapy is first initiated or doses are increased.
• Behavioral changes: Some animals may show excitement, agitation, or paradoxical behavioral responses.
• Hypotonia: Decreased muscle tone may occur in some patients.
• Hypersalivation and respiratory secretions: Increased salivation or upper respiratory secretions may be observed.
• Gastrointestinal signs: Vomiting, diarrhea, or constipation have been reported occasionally.
• Liver effects (cats): Acute hepatic injury has been reported with benzodiazepines in cats, and similar effects may occur with clonazepam.

Overdose

Clonazepam overdoses generally cause central nervous system depression, although paradoxical neurologic signs may occur in some animals.

• Common signs: Sedation, ataxia, agitation, vomiting, or disorientation.
• Paradoxical reactions: Hyperactivity, vocalization, or behavioral agitation may occur in some animals.
• Severe toxicity: Large overdoses may cause profound CNS depression, respiratory depression, or hypotension.
• Management: Supportive care is usually sufficient for mild cases. Severe CNS or respiratory depression may be treated with flumazenil, although repeated dosing may be required.

Key Notes

Practical clinical considerations that may help optimize the use of clonazepam in dogs and cats during treatment of neurologic or behavioral conditions:

• Adjunctive anticonvulsant role: Clonazepam is usually used as an add-on medication for seizure management rather than as a primary anticonvulsant.
• Rapid CNS penetration: The drug crosses the blood–brain barrier quickly, which contributes to its neurologic effects.
• Variable oral bioavailability in dogs: Absorption after oral administration may vary widely between patients.
• Use before predictable anxiety triggers: For situational anxiety (e.g., storms or stressful events), administration about one hour before the expected trigger may improve effectiveness.
• Active central nervous system distribution: Clonazepam distributes rapidly into brain tissue due to its high lipid solubility.
• Controlled substance status: Clonazepam is classified as a Schedule IV controlled drug in some countries and should be stored and prescribed according to applicable regulations.